Although the benefit seen in the CAVE study needs Phase III confirmation, the analysis showed that plasma ctDNA testing may help identify best responders.
The data may result in another option for patients in the crowded first-line ALK-positive lung cancer market, though progression-free survival data are not yet mature.
In an analyst briefing, Pfizer described plans to advance several precision oncology assets in earlier disease settings and in combination with other therapies.
A Sanford Cancer Center team is genomically profiling head and neck squamous cell cancer samples to look for biomarkers of immunotherapy and chemoradiation response.
The company said that the third-generation TKI achieved its primary endpoint of improved progression-free survival versus Xalkori in a Phase III trial.
In the Phase II TAPUR trial, palbociclib monotherapy demonstrated "modest antitumor activity" in heavily pretreated non-small cell lung cancer patients with CDKN2A alterations.
In another study at ASCO, the immunotherapy showed benefits as maintenance therapy in advanced bladder cancer patients, regardless of PD-L1 expression status.
